Introduction This randomised double-blind placebo-controlled study evaluated the addition
of cediranib, an inhibitor of vascular endothelial growth factor receptors 1–3, to standard …

Purpose This phase II/III double-blind study assessed efficacy and safety of cediranib with
standard chemotherapy as initial therapy for advanced non–small-cell lung cancer …

INTRODUCTION: Cediranib, a potent vascular endothelial growth factor inhibitor,
demonstrated broad pre-clinical anti-tumour activity. This study evaluated escalating …

Introduction: The purpose of this study was to assess the safety and efficacy of gemcitabine
and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for …

Cediranib (AZD2171; Recentin, AstraZeneca, Wilmington, Delaware) is a once-daily oral
tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2, and 3 …

Purpose To evaluate safety and tolerability of cediranib, a highly potent and selective
vascular endothelial growth factor signaling inhibitor, in Japanese patients with advanced …

6023 Background: Cediranib is an oral, highly potent and selective inhibitor of VEGF
signaling, with activity versus VEGFR-1,-2 and-3. FDG-PET has previously been shown to …

Background Cediranib is a highly potent vascular endothelial growth factor (VEGF) signaling
inhibitor of all three VEGF receptors. This phase I, single-center, dose-finding study was …

Background Hypertension (HTN), a recognized adverse effect of angiogenesis inhibitors,
may be a potential biomarker of activity of these agents. We conducted a retrospective …

Background: The Notch signalling pathway has been implicated in tumour initiation,
progression, angiogenesis and development of resistance to vascular endothelial growth …